The diagnostic value of machine learning for the classification of malignant bone tumor: a systematic evaluation and meta-analysis

Abstract

BackgroundMalignant bone tumors are a type of cancer with varying malignancy and prognosis. Accurate diagnosis and classification are crucial for treatment and prognosis assessment. Machine learning has been introduced for early differential diagnosis of malignant bone tumors, but its performance is controversial. This systematic review and meta-analysis aims to explore the diagnostic value of machine learning for malignant bone tumors.MethodsPubMed, Embase, Cochrane Library, and Web of Science were searched for literature on machine learning in the differential diagnosis of malignant bone tumors up to October 31, 2022. The risk of bias assessment was conducted using QUADAS-2. A bivariate mixed-effects model was used for meta-analysis, with subgroup analyses by machine learning methods and modeling approaches.ResultsThe inclusion comprised 31 publications with 382,371 patients, including 141,315 with malignant bone tumors. Meta-analysis results showed machine learning sensitivity and specificity of 0.87 [95% CI: 0.81,0.91] and 0.91 [95% CI: 0.86,0.94] in the training set, and 0.83 [95% CI: 0.74,0.89] and 0.87 [95% CI: 0.79,0.92] in the validation set. Subgroup analysis revealed MRI-based radiomics was the most common approach, with sensitivity and specificity of 0.85 [95% CI: 0.74,0.91] and 0.87 [95% CI: 0.81,0.91] in the training set, and 0.79 [95% CI: 0.70,0.86] and 0.79 [95% CI: 0.70,0.86] in the validation set. Convolutional neural networks were the most common model type, with sensitivity and specificity of 0.86 [95% CI: 0.72,0.94] and 0.92 [95% CI: 0.82,0.97] in the training set, and 0.87 [95% CI: 0.51,0.98] and 0.87 [95% CI: 0.69,0.96] in the validation set.ConclusionMachine learning is mainly applied in radiomics for diagnosing malignant bone tumors, showing desirable diagnostic performance. Machine learning can be an early adjunctive diagnostic method but requires further research and validation to determine its practical efficiency and clinical application prospects.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023387057.